{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:45:03Z","timestamp":1783597503377,"version":"3.55.0"},"reference-count":37,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Norwegian governement, Norwegian Research Center for Agonist Treatment of Substance Use Disorders","award":["R-11141-D11722"],"award-info":[{"award-number":["R-11141-D11722"]}]},{"name":"National program for clinical treatment research in the specialist health service in Norway","award":["F-12782-D10987-01"],"award-info":[{"award-number":["F-12782-D10987-01"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,26]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>There is limited evidence on how to effectively treat individuals from marginalised populations with dependence on amphetamine and\/or methamphetamine (collectively referred to hereafter as amphetamine dependence). The disease burden is extremely high in this population, especially related to psychiatric comorbidities, cardiovascular complications, injection-related infections and poor social functioning. ATLAS4Dependence is a multi-centre randomised, placebo-controlled, double-blind trial that will investigate the effectiveness and safety of substitution treatment with dextroamphetamine compared with placebo in people with amphetamine dependence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      The trial will recruit 226 adult patients in several outpatient clinics in Norway.\u202fInclusion criteria comprise individuals with amphetamine dependence, defined as use on three or more days per week during the past 28 days, who currently inject or have formerly injected drugs. This includes individuals both with and without comorbid opioid dependence, as well as those currently receiving or not receiving opioid agonist treatment. Participants will be randomly assigned 1:1 to receive either dextroamphetamine or placebo for 12 weeks. Flexible doses within the range of 30\u2013120\u2009mg daily will be provided based on individual assessments. The participants in both arms will be offered standard psychosocial and medical follow-up in accordance with current clinical practice. The endpoint assessments will be conducted at 12 weeks with weekly self-reports and safety assessments and a follow-up assessment at 52 weeks. The primary objective of the study is to assess the impact of 12 weeks daily prescribed oral dextroamphetamine versus placebo on the use of illicit amphetamines as well as on the total amount of amphetamines used (including both illicit and prescribed sources). Secondary outcomes are the differences between the groups at 12 weeks regarding psychological distress, symptoms of psychosis, quality of life, cardiovascular risk factors, injection-related infections, executive functioning, attention-deficit hyperactivity disorder-related symptoms, sleep, violence risk, fatigue, symptoms of craving and withdrawal, treatment retention, days of use of illicit amphetamines and use at 4 weeks and 8 weeks during the intervention period, use of other illicit substances and alcohol, as well as a cost-effectiveness analysis (using private economy, criminal activity and health service utilisation) and a qualitative approach to assess overall experiences with the study intervention. Analysis and reporting will follow the Consolidated Standards of Reporting Trials guidelines. All tests will be two-sided. Descriptive results and the estimated effectiveness will be presented with 95% CIs. The difference between the groups at the primary time point (at the end of the 12-week trial) will be assessed using \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test (for use of illicit amphetamines measured by monthly urine tests) and Analysis of Covariance (ANCOVA) (for weekly self-reported total amount of amphetamines). Analyses for the primary endpoint will be undertaken on an intention-to-treat basis and reported on as such, but sensitivity analyses with per protocol analyses will also be presented.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study is approved by European Medicines Agency, Clinical Trial Information System (CTIS). Written informed consent will be obtained from all patients. Study results will be published in international peer-reviewed medical journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>CTIS 2023-510404-44-00.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-095383","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:00:25Z","timestamp":1761033625000},"page":"e095383","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of dextroamphetamine substitution on the use of illicit amphetamines in adults with amphetamine dependence: a study protocol for the multicentre double blind randomised controlled trial ATLAS4Dependence"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1242-1972","authenticated-orcid":false,"given":"Fatemeh","family":"Chalabianloo","sequence":"first","affiliation":[{"name":"Department of Addiction Medicine, Norwegian Research Centre for Agonist Treatment of Substance Use Disorders (NORCATS), Haukeland University Hospital, Bergen, Vestland, Norway"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Vestland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8757-2092","authenticated-orcid":false,"given":"Lars T","family":"Fadnes","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Norwegian Research Centre for Agonist Treatment of Substance Use Disorders (NORCATS), Haukeland University Hospital, Bergen, Vestland, Norway"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Vestland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Mordal","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Norwegian Research Centre for Agonist Treatment of Substance Use Disorders (NORCATS), Haukeland University Hospital, Bergen, Vestland, Norway"},{"name":"Department of Addiction Medicine, Vestfold Hospital Trust, T\u00f8nsberg, Vestfold, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Spigset","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, St Olav\u2019s Hospital HF, Trondheim, Tr\u00f8ndelag, Norway"},{"name":"Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Tr\u00f8ndelag, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else-Marie","family":"L\u00f8berg","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Haukeland University Hospital, Bergen, Vestland, Norway"},{"name":"Department of Clinical Psychology, University of Bergen, Bergen, Vestland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Halm\u00f8y","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Haukeland University Hospital, Bergen, Vestland, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Vestland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torgeir Gilje","family":"Lid","sequence":"additional","affiliation":[{"name":"Centre for Alcohol and Drug Research (KORFOR), Stavanger University Hospital, Stavanger, Rogaland, Norway"},{"name":"Faculty of Health Sciences, University of Stavanger, Stavanger, Rogaland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Dahl","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Norwegian Research Centre for Agonist Treatment of Substance Use Disorders (NORCATS), Haukeland University Hospital, Bergen, Vestland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Tore","family":"Daltveit","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Norwegian Research Centre for Agonist Treatment of Substance Use Disorders (NORCATS), Haukeland University Hospital, Bergen, Vestland, Norway"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Vestland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f5rg","family":"Assmus","sequence":"additional","affiliation":[{"name":"Centre for Clinical Research, Haukeland University Hospital, Bergen, Vestland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander H","family":"Erga","sequence":"additional","affiliation":[{"name":"Centre for Alcohol and Drug Research (KORFOR), Stavanger University Hospital, Stavanger, Rogaland, Norway"},{"name":"Department of Social Studies, University of Stavanger, Stavanger, Rogaland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-2947","authenticated-orcid":false,"given":"Kristin","family":"K Solli","sequence":"additional","affiliation":[{"name":"Department of Research and Development in Mental Health, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"Division of Mental Health and Addiction, Vestfold Hospital Trust, T\u00f8nsberg, Vestfold, Norway"},{"name":"Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Fredrik","family":"Askjer","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Vestfold Hospital Trust, T\u00f8nsberg, Vestfold, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna A K","family":"Hansen","sequence":"additional","affiliation":[{"name":"Division of Mental Health and Addiction, Finnmark Hospital Trust, Hammerfest, Finnmark, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ohldieck","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Norwegian Research Centre for Agonist Treatment of Substance Use Disorders (NORCATS), Haukeland University Hospital, Bergen, Vestland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-8305","authenticated-orcid":false,"given":"Nadine","family":"Ezard","sequence":"additional","affiliation":[{"name":"Alcohol and Drug Service, St Vincent\u2019s Hospital Sydney, Darlinghurst, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Clinical Research and Improvement Network, South Eastern Sydney Local Health District, Kogarah, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell Arne","family":"Johansson","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Norwegian Research Centre for Agonist Treatment of Substance Use Disorders (NORCATS), Haukeland University Hospital, Bergen, Vestland, Norway"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Vestland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"2025120415070277000_15.10.e095383.1","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/add.14706","article-title":"Mortality among people with regular or problematic use of amphetamines: a systematic review and meta-analysis","volume":"114","author":"Stockings","year":"2019","journal-title":"Addiction"},{"key":"2025120415070277000_15.10.e095383.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05563-3"},{"key":"2025120415070277000_15.10.e095383.3","first-page":"987","article-title":"Alcohol and Drug Use Collaborators. The global burden of diseases attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis","volume":"5","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2025120415070277000_15.10.e095383.4","unstructured":"European Union Drugs Agency . Synthetic stimulants \u2013 the current situation in europe. European Drug Report; 2024."},{"key":"2025120415070277000_15.10.e095383.5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13011-021-00354-1","article-title":"Substance use and symptoms of mental health disorders: a prospective cohort of patients with severe substance use disorders in Norway","volume":"16","author":"Aas","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2025120415070277000_15.10.e095383.6","doi-asserted-by":"crossref","unstructured":"Fadnes LT , Aas CF , Vold JH , et al . Integrated treatment of hepatitis C virus infection among people who inject drugs: a multicenter randomized controlled trial (INTRO-HCV). PLoS Med 2021;18. doi:10.1371\/journal.pmed.1003653","DOI":"10.1371\/journal.pmed.1003653"},{"key":"2025120415070277000_15.10.e095383.7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.5694\/mja2.52039","article-title":"Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study","volume":"219","author":"Black","year":"2023","journal-title":"Med J Aust"},{"key":"2025120415070277000_15.10.e095383.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02717.x"},{"key":"2025120415070277000_15.10.e095383.9","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.307"},{"key":"2025120415070277000_15.10.e095383.10","doi-asserted-by":"crossref","unstructured":"Ezard N , Clifford B , Dunlop A , et al . Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. BMJ Open 2021;11. doi:10.1136\/bmjopen-2020-044696","DOI":"10.1136\/bmjopen-2020-044696"},{"key":"2025120415070277000_15.10.e095383.11","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/add.14755","article-title":"Pharmacotherapy for methamphetamine\/amphetamine use disorder \u2013 a systematic review and metaanalysis","volume":"114","author":"Chan","year":"2019","journal-title":"Addiction"},{"key":"2025120415070277000_15.10.e095383.12","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00711-x"},{"key":"2025120415070277000_15.10.e095383.13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13643-016-0370-x","article-title":"Effectiveness and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and metaanalysis","volume":"5","author":"Bhatt","year":"2016","journal-title":"Syst Rev"},{"key":"2025120415070277000_15.10.e095383.14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/add.16347","article-title":"Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"119","author":"Sharafi","year":"2024","journal-title":"Addiction"},{"key":"2025120415070277000_15.10.e095383.15","doi-asserted-by":"crossref","unstructured":"Oliva HNP . Safety of stimulants across patient populations: a metaanalysis. JAMA Netw Open 2025;8. doi:10.1001\/jamanetworkopen.2025.9492","DOI":"10.1001\/jamanetworkopen.2025.9492"},{"key":"2025120415070277000_15.10.e095383.16","unstructured":"Norwegian Medical Agency . Attentin (dexamphetamine). Industrial medicinal product. n.d."},{"key":"2025120415070277000_15.10.e095383.17","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"2025120415070277000_15.10.e095383.18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/08039488.2018.1468923","article-title":"Screening for intellectual disabilities: validation of the Hayes Ability Screening Index","volume":"72","author":"Braatveit","year":"2018","journal-title":"Nord J Psychiatry"},{"key":"2025120415070277000_15.10.e095383.19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/jat\/bkae038","article-title":"Enantiomer-specific analysis of amphetamine in urine, oral fluid and blood","volume":"48","author":"Bakke","year":"2024","journal-title":"J Anal Toxicol"},{"key":"2025120415070277000_15.10.e095383.20","unstructured":"European Agency for Evaluation of Medical Products . Guidelines for Clinical Practice. Including Errata. 2002."},{"key":"2025120415070277000_15.10.e095383.21","unstructured":"ANRS . Scale to grade the severity of adverse events in adults. 2008. Available: http:\/\/www.anrs.fr\/content\/download\/2242\/12805\/file\/ANRS-GradeEI-V1-En-2008.pdf"},{"key":"2025120415070277000_15.10.e095383.22","doi-asserted-by":"publisher","DOI":"10.1080\/08039480310000932"},{"key":"2025120415070277000_15.10.e095383.23","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1093\/schbul\/sby156","article-title":"A crossnational investigation of hallucinationlike experiences: the ECLECTIC study","volume":"45","author":"Siddi","year":"2019","journal-title":"Schizophr Bull"},{"key":"2025120415070277000_15.10.e095383.24","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291704002892"},{"key":"2025120415070277000_15.10.e095383.25","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025120415070277000_15.10.e095383.26","unstructured":"P\u00e9rez-Parra JE , Restrepo-de-Mej\u00eda F . The Trail Making Test (part B) is associated with working memory. Appl Neuropsychol Adult 2023;1\u20139. doi:10.1080\/23279095.2023.2181290"},{"key":"2025120415070277000_15.10.e095383.27","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01708-w"},{"key":"2025120415070277000_15.10.e095383.28","unstructured":"Fischer JA , Roche AM , Duraisingam V . Amphetamine Withdrawal Questionnaire (AWQ): Description, Strengths and Knowledge Gaps. NCETA, Flinders University, 2021."},{"key":"2025120415070277000_15.10.e095383.29","doi-asserted-by":"publisher","DOI":"10.1177\/088626000015012003"},{"key":"2025120415070277000_15.10.e095383.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-9457(00)00065-4"},{"key":"2025120415070277000_15.10.e095383.31","doi-asserted-by":"publisher","DOI":"10.1257\/jel.52.1.5"},{"key":"2025120415070277000_15.10.e095383.32","unstructured":"Rosner B . Fundamentals of Biostatistics. 7th edn. Boston: Brooks\/Cole, Cengage Learning, 2011."},{"key":"2025120415070277000_15.10.e095383.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04337-3"},{"key":"2025120415070277000_15.10.e095383.34","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1111\/add.16200","article-title":"Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis","volume":"118","author":"Bharat","year":"2023","journal-title":"Addiction"},{"key":"2025120415070277000_15.10.e095383.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17965-3"},{"key":"2025120415070277000_15.10.e095383.36","unstructured":"OECD . List of oecd series on principles of good laboratory practice and compliance monitoring. 1998."},{"key":"2025120415070277000_15.10.e095383.37","unstructured":"International Committee of Medical Journal Editors . Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. n.d. Available: http:\/\/www.icmje.org\/recommendations\/"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-095383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:11:12Z","timestamp":1764889872000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-095383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,20]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjopen-2024-095383"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095383","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}